EUR/USD likely to find a peak near 1.25: UBS
BOSTON—Tatsis Ourania, Executive Vice President and Chief Regulatory and Quality Officer at Vertex Pharmaceuticals (NASDAQ:VRTX), a prominent biotechnology company with a market capitalization of $123 billion and strong financial health according to InvestingPro analysis, recently sold 354 shares of the company’s common stock. The transaction, executed on February 25, 2025, was valued at approximately $170,256, with a per-share price of $480.95. This sale was conducted under a pre-established trading plan in accordance with Rule 10b5-1, which was set up on February 29, 2024. Following this transaction, Dr. Tatsis holds 64,031 shares of Vertex Pharmaceuticals. The stock has shown strong momentum with a 19.28% gain year-to-date, and according to InvestingPro’s Fair Value analysis, the stock appears to be fairly valued at current levels.
Additionally, on February 24, Dr. Tatsis disposed of 3,310 shares at a price of $483.28 per share, totaling $1,599,656. After these transactions, she retains significant holdings in the company, reflecting her continued investment in Vertex Pharmaceuticals, which maintains healthy liquidity with a current ratio of 2.69 and has demonstrated solid revenue growth of 11.66% over the last twelve months. For comprehensive insider trading analysis and 12 additional exclusive ProTips, visit InvestingPro.
In other recent news, Vertex Pharmaceuticals Incorporated has been the focus of several analyst reports and developments. TD Cowen reaffirmed its Buy rating with a $525 price target, highlighting Vertex’s strong fourth-quarter performance, where cystic fibrosis revenues reached $2.9 billion, surpassing the consensus estimate. The firm noted that Vertex’s full-year 2025 revenue guidance is between $11.75 billion and $12 billion, with expected growth driven by new product launches, including Journavx. Truist Securities also increased its price target for Vertex to $520, maintaining a Buy rating due to positive feedback on the launches of Alyftrek and Journavx.
RBC Capital Markets adjusted its price target for Vertex to $408, maintaining a Sector Perform rating. The firm cited enthusiasm for the non-opioid drug Journavx but expressed caution about the pace of its rollout due to reimbursement dynamics. Meanwhile, BMO Capital Markets maintained its Outperform rating with a $545 target, emphasizing Vertex’s growth potential through 2025, driven by Alyftrek and Journavx.
DA Davidson reaffirmed its Buy rating and $62 price target, noting Vertex’s resilience in the face of industry challenges. The firm’s analysis suggests confidence in Vertex’s ability to navigate risks that have affected similar companies. Additionally, Vertex reported a top-line beat for the fourth quarter of 2024, with revenues exceeding consensus by 5%, though operating expenses were slightly higher than expected. The company also announced the upcoming retirement of Chief Operating Officer Stuart Arbuckle, effective July 1, 2025.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.